⅐ NO) signaling pathways and lipid oxidation reactions are of central importance in both the maintenance of vascular homeostasis and the progression of vascular disease. Because both of these pathways involve free radical species that can also react together at extremely fast rates, convergent interactions between these pathways are expected. Biochemical and cell biology studies have defined multiple interactions of ⅐ NO with oxidizing lipids that could lead to either vascular protection or potentiation of inflammatory vascular injury. For example, low levels of ⅐ NO generated by endothelial nitric oxide synthase can terminate propagating lipid radicals and inhibit lipoxygenases, reactions that would be protective. Alternatively, if generated at elevated levels, for example, after inducible nitric oxide synthase expression in inflammation, NO is an endogenously generated mediator of smooth muscle relaxation and inhibitor of platelet/leukocyte activation that is essential for maintenance of vascular homeostasis. In many vascular pathologies, altered ⅐ NO generation rates, often coupled with accelerated ⅐ NO removal through poorly understood pathways, leads to impaired ⅐ NO signaling and secondary generation of toxic ⅐ NO-derived species. 1-6 Reaction of ⅐ NO with O 2 ⅐Ϫ , yielding peroxynitrite (ONOO -), accounts for a major part of the accelerated ⅐ NO removal 2-6 but is not the only mechanism involved, because endothelium-derived relaxing factor (EDRF) activity is often incompletely restored by O 2 ⅐Ϫ scavengers. [7] [8] [9] This suggests that the reaction of ⅐ NO with other biochemical "sinks" can also account for enhanced rates of EDRF consumption. Further evidence for alterations in ⅐ NO metabolism in vascular disease is provided by observations of Original
the tyrosine oxidation/nitration product 3-nitrotyrosine (NO 2 -tyr) and elevations in inducible nitric oxide synthase (iNOS or NOS2) activity. For example, both NO 2 -tyr and NOS2 expression are consistently elevated clinically (transplant coronary artery disease, atherosclerotic lesions, cardiac allograft rejection, and myocardial inflammation) and in animal models of vascular disease (hypercholesterolemia-induced atherosclerosis, balloon-injured arteries, ischemic heart injury, and myocardial inflammation) (reviewed in Reference 10; see also .
Increased lipid oxidation is a characteristic feature of inflammatory vascular diseases and has been suggested to sometimes play a causative role, although this has not been conclusively proven. 18 -24 The candidate mechanisms that generate oxidized lipids in vivo are numerous and include metal-dependent Fenton oxidation, enzyme-catalyzed oxidation by lipoxygenase (LOX) or myeloperoxidase (MPO), reaction with hypochlorous acid (HOCl), cell-dependent oxidation via a diversity of O 2 ⅐Ϫ and H 2 O 2 -generating oxidases, and, finally, oxidation by ⅐ NO-derived reactive species (eg, ⅐ NO 2 , nitryl chloride [NO 2 C], and ONOO -). [25] [26] [27] [28] [29] [30] [31] [32] In particular, support for a pathogenic role of LOX-catalyzed lipid oxidation in vivo in atherogenesis includes the observations that functional 15-LOX and its products are present in human and rabbit lesions, 21, 33, 34 disruption of the mouse 12/15-LOX gene diminishes atherosclerosis in apoE-deficient mice, and inhibition of 15-LOX prevents development of atherosclerosis in cholesterol-fed rabbits. 35, 36 In contrast, targeted overexpression of rabbit macrophage 15-LOX prevents diet-induced atherosclerosis. 37 In the vasculature, nitric oxide ( ⅐ NO) and lipid oxidation signaling pathways can potentially interact at several levels. Because of the diversity of the biochemical pathways involved, an understanding of how these processes might impact on vascular homeostasis is important. In this review, we summarize current knowledge of how lipid oxidation pathways and ⅐ NO-derived species interact at a chemical and cellular level and describe what is known about how these interactions might influence disease progression. 
Reactions of NO

Peroxynitrite-Induced Lipid Oxidation and Nitration
Peroxynitrite is unique as a lipid oxidant, because it mediates peroxidation of unsaturated fatty acids in the absence of transition metal catalysts. 29 Peroxynitrite is more than two orders of magnitude more potent than H 2 O 2 in catalyzing lipid oxidation in vitro and, in contrast to transition metal catalysts, mediates LDL oxidation even in the presence of lipophilic antioxidants. 60 In vitro, ONOO -oxidizes diverse classes of lipids (eg, purified fatty acids, neutral lipids and phospholipids, and lipophilic antioxidants and LDL lipids) forming conjugated diene, malondialdehyde, lipid peroxide, lipid hydroxide, F 2 -isoprostane, and oxysterol products. 29,44,50,60 -63 In the case of LDL, this results in an LDL derivative recognized by the macrophage scavenger receptor. 64 In addition to oxidizing lipids, ONOO -mediates linoleate and LDL cholesteryl linoleate nitration to the derivative LNO 2 65 (also A. Bloodsworth and B.A. Freeman, unpublished data, 2001 ). This reaction proceeds via either hydrogen abstraction by ⅐ NO 2 or addition mechanisms involving NO 2 ϩ ( Figure 2) . A role for ONOO -in initiating lipid oxidation in atherosclerosis has been suggested 66 ; however, this requires that the barrier of competing reactions with thiols be overcome, which are present intracellularly at concentrations of up to 10 mmol/L (kϭ5.9ϫ10 3 [mol/L] -1 ⅐s -1 for ONOO -reaction with cysteine).
Reactions of the ⅐ NO Metabolites ⅐ NO 2 and NO 2 Cl With Unsaturated Lipids
Several reactive nitrogen species derived from ⅐ NO oxidize and nitrate unsaturated fatty acids and their methyl/ethyl esters in vitro. Nitrogen dioxide will both oxidize and nitrate unsaturated lipids, with nitration occurring by hydrogen abstraction and addition reactions. 28, 65, [67] [68] [69] [70] [71] [72] [73] [74] These reactions result in formation of a complex mixture of products including nitrated lipid derivatives and alkylnitrites, including those shown in Figure 3 . 75 Nitration of methyl linoleate and linolenate by ⅐ NO 2 proceeds via initial hydrogen abstraction to form a carbon-centered alkyl radical, which at low oxygen tensions combines with ⅐ NO 2 to form allylic nitro compounds ( Figure 2 ). The yield of oxygen-containing lipid products (eg, LOOH, LOH, etc) formed by ⅐ NO 2 oxidation thus depends on the concentration of O 2 that will facilitate peroxidation reactions. 28 At high O 2 concentrations, for example, in lung lining fluid, ⅐ NO 2 will predominantly mediate lipid oxidation. Conversely, at low O 2 tension (eg, within an inflamed hypoxic organ or microvessel), nitration reactions may preferentially occur. Somewhat analogous to ⅐ NO, ⅐ NO 2 can also react at diffusion-limited rates with peroxyl and alkoxyl radicals, leading to inhibition of peroxidation and formation of novel N-containing lipid derivatives. 46, 76 The oxidation of nitrite (NO 2 -) by MPO-derived hypochlorous acid (HOCl) will yield nitryl chloride (NO 2 Cl), 77, 78 which, in purified LDL, depletes ␤-carotene and ␣-tocopherol, initiates lipid oxidation, forms 3-nitrotyrosine, 27 and can yield an LDL particle similar to that found in foam cells. The direct oxidation of NO 2 -by MPOϩH 2 O 2 yields ⅐ NO 2 and also oxidizes LDL lipids to a proatherogenic particle. 79 -81 Oxidation and nitration of membrane lipids by MPO may be operative in atherogenesis, because products of MPO activity are found in vascular lesions 25, 82 ; however, this has not been conclusively proven. Finally, acidification of NO 2 -forms nitrous acid (HONO), which decomposes to nitrosating and nitrating species including N 2 O 3 and ⅐ NO 2 . Reaction of ethyl linoleate with HONO yields several nitrated lipids, including nitroalkenes and nitroalcohols, whereas reaction of lipid hydroperoxides (LOOH) with HONO forms nitroepoxylinoleate 65, 75 (Figure 4) . Formation of HONO is favored at pHϽ4; therefore, if these reactions are to occur in the vasculature, they will require acidic microenvironments, for example, in the phagolysosomes of neutrophils or macrophages.
NO-Derived Reactive Species Modulate the Activity and Expression of Lipid Oxidation Enzymes
Enzymes such as LOX, prostaglandin endoperoxide H synthase (PGHS), and cytochrome P450 (CYP) that oxidize lipids to bioactive eicosanoids play critical signaling roles in the regulation of vascular cell function and inflammatory responses and are ubiquitously expressed by virtually all vascular cells under both physiological and inflammatory conditions ( Figure 5 ). Generally, lipid oxidation by these enzymes involves formation of enzyme-bound radical intermediates, including lipid alkyl (L ⅐ ) and peroxyl (LOO ⅐ ) radical species. Free peroxyl or alkyl radicals react with ⅐ NO at diffusion-limited rates. Thus, reaction of ⅐ NO with enzymebound lipid radicals will modulate rates of eicosanoid product formation and decrease bioavailable concentrations of ⅐ NO, as discussed below. 46 -49 In addition to lipid radicals, these enzymes form several other intermediates that can react with NO during turnover, including amino acid or porphyrin radicals and various redox states of iron. In the next sections, the known interactions of ⅐ NO with the various enzyme intermediates formed during catalysis are discussed.
Prostaglandin Endoperoxide H Synthase (PGHS)
Prostaglandins are generated via arachidonate oxygenation by PGHS, of which there are both constitutive (PGHS-1: stomach, gut, kidney, and platelets) and inducible (PGHS-2: fibroblasts and macrophages) isoforms. Under inflammatory conditions, both NOS2 and PGHS-2 expression is upregulated in tandem by proinflammatory cytokines including interleukin-1 (IL-1) and tumor necrosis factor, indicating that high levels of both prostaglandin and ⅐ NO will be produced in concert in vivo. [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] Reactive nitrogen species have multiple effects on PGHS activity. Purified PGHS-1 is not significantly inhibited by ⅐ NO; however, in several cell types, including endothelial cells and platelets, ⅐ NO highly stimulates prostaglandin production. [93] [94] [95] [96] In other cell types, ⅐ NO suppresses lipopolysaccharide (LPS)-induced PGHS-2 expression, resulting in apparent enzyme inhibition. 97, 98 Finally, in NOS2 knockout mice, less urinary prostaglandin E 2 is found, although platelets from these animals generate more thromboxane B 2 in vitro. 99 NO can interact in several ways with PGHS, by forming an Fe-nitrosyl complex, acting as a peroxidase-reducing substrate, directly terminating the catalytic tyrosyl radical in the enzyme active site, and theoretically, by termination of enzyme-bound lipid radicals 93,100 -102 ( Figure 6 ). Formation of the nitrosyl complex of PGHS by ⅐ NO is favored for the ferrous form, whereas the K d for formation of the ferric ⅐ NO complex is very high, being 0.92 mmol/L for ⅐ NO. 102 Because the ferrous enzyme is not involved in enzyme catalysis and nonbiological (mmol/L) concentrations of ⅐ NO would be required for significant metal center reaction to occur, nitrosyl complex formation is unlikely to be a mechanism of PGHS activity modulation by ⅐ NO in vivo. Although termination of tyrosyl radicals by ⅐ NO proceeds at essentially diffusion-limited rates, it is intriguing that PGHS is not more readily inhibited in vitro by ⅐ NO. Possible explanations are that ⅐ NO-tyrosyl radical reactions are readily reversible, or by acting as a peroxidase-reducing substrate, ⅐ NO alternatively contributes to enzyme activation. 93, 103 Peroxynitrite is also an 
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Lipoxygenases (LOX)
Lipoxygenases are non-heme iron-containing enzymes that catalyze oxidation of arachidonate or linoleate to bioactive lipid hydroperoxides. In mammalian cells, at least three isoforms are known with the best characterized, 5-LOX, found mainly in leukocytes. 106 12-LOX isoforms are present in platelets and monocytes. 107, 108 15-LOX is expressed in reticulocytes during maturation into erythrocytes, where it plays a central role in intracellular membrane degradation. In human monocytes, expression of 15-LOX is induced by IL-4 and IL-13. 109, 110 A role for 15-LOX in the initiation and progression of atherosclerosis has also been suggested by the observation of 15-LOX products at elevated levels in atherosclerotic lesions. 21, 22, 34, 111 Lipoxygenases 43 which would be expected to occur at nanomolar concentrations of ⅐ NO present in vivo. After this reaction, dissociation and hydrolysis of the organic peroxynitrite (LOONO) gives LOOH and NO 2 -as products (Figure 7) . Because the LOX catalytic cycle is not completed, reoxidation of the enzyme-bound iron is required. 43 Thus, because ⅐ NO reaction occurs after O 2 insertion into the fatty acid substrate, the LOX product profile is unchanged, the rate of product generation is suppressed, and ⅐ NO is consumed.
Cytochrome P450 (CYP)
CYP enzymes are a ubiquitously expressed family of heme proteins that play major roles in xenobiotic metabolism and lipid oxidation. Nonhepatic CYP arachidonate metabolites also act as intracellular signaling molecules in vascular tissue. For example, the CYP4A product 20-hydroxyeicosatetraenoic acid (20-HETE) is a potent vasoconstrictor whose generation in vascular smooth muscle cells is inhibited by ⅐ NO. 120 A second product, 11,12-EET, is produced by endothelial cells, avidly esterified into endothelial phospholipid pools, and mediates vascular relaxation, possibly accounting for a component of the presently undescribed endothelium-derived hyperpolarizing factor activity. [121] [122] [123] Preformed EETs in endothelial membranes can influence vascular function by altering membrane characteristics, ion transport, or lipid-dependent signaling pathways. 124 For example, one isomer, 5,6-EET, mediates vasodilation by either increasing ⅐ NO production through stimulating Ca 2ϩ influx into endothelial cells 125 or by directly activating smooth muscle K ca channels. 121, 126 NO has been shown to inhibit the CYP enzymes thromboxane synthase and prostacyclin synthase in vitro. This can have a significant effect on vascular function, in that these enzymes generate thromboxane and prostacyclin, eicosanoid mediators that are central in regulation of platelet aggregation and smooth muscle tone in vivo. 127 Formation of nitrosyl complexes has been observed for some CYP isoforms; however, the detailed mechanisms by which ⅐ NO interacts with CYP have not been elucidated.
Catalytic
⅐ NO Consumption by Lipid Oxidation Enzymes PGHS and LOX catalyze ⅐ NO consumption via reaction with intermediates formed during enzyme turnover, a reaction first confirmed using purified enzymes and isolated vascular cells, including platelets and monocytes 43, 103 (also M.J. Coffey and V.B. O'Donnell, unpublished data, 2001). In these cell models, the rates and amounts of ⅐ NO consumed are high, relative to expected rates and amounts of ⅐ NO generated, suggesting that these reactions might play a role in both physiological and pathological ⅐ NO removal in vascular cells. Figure 8A ). 43 Through acting as a peroxidase-reducing substrate, ⅐ NO is also consumed rapidly by both purified PGHS-1 plus arachidonate and by the A23187 or thrombin-activated PGHS-1 activity of human platelets. 103 Rates of ⅐ NO removal by platelets are fast enough to deplete micromolar ⅐ NO levels and potently prevent ⅐ NO-dependent activation of platelet sGC, thus causing platelets to overcome the antiaggregatory effects of ⅐ NO ( Figure 8B ). This reveals a second novel proaggregatory function for PGHS-1 in addition to its generation of proaggregatory eicosanoids-specifically, catalytic consumption of the antiaggregatory species ⅐ NO.
Lipid Oxidation Products Regulate NO Bioactivity
Although ⅐ NO production regulates the induction and activity of lipid oxidation enzymes, their eicosanoid products can conversely modulate rates of cellular ⅐ NO production. In platelets, activation of nitric oxide synthase is inhibited by aspirin or indomethacin, an effect that is overcome by addition of thromboxane A 2 . 128 In the murine macrophage cell line J774, induction of NOS2 by LPS is inhibited by indomethacin, 129 inferring involvement of PGHS products. Activation of LOX also leads to increases in NOS2 expression. For example, the nonspecific LOX inhibitor nordihydroguaiaretic acid prevents induction of NOS2 in myocytes or smooth muscle by IL-1 or LPS, respectively. 130, 131 In addition, isolated peritoneal macrophages from 12-LOX knockout mice display 50% less NO 2 -ϩNO 3 -generation after interferon-␥/LPS challenge. 132 Finally, oxidized LDL can have opposing effects on ⅐ NO bioactivity, either through lysolecithin-dependent impairment of endotheliumdependent arterial relaxation or by causing induction of NOS2. 133, 134 Conclusions: Implications for Vascular Disease NO and ⅐ NO-derived reactive species interact with lipid oxidation pathways via multiple mechanisms in vitro that are only recently being revealed. Because both processes are central to vascular regulation, an understanding of the particular interactions that are involved in pathogenesis of vascular disease in vivo is important. A role for ⅐ NO acting as an antioxidant in vivo by inhibiting proatherogenic lipid oxidation is suggested, because increasing ⅐ NO bioactivity through L-arginine supplementation has been successful in attenuating vascular dysfunction in hypercholesterolemic rabbits. [135] [136] [137] In humans, results have been mixed, with intravenous infusion of L-arginine acutely improving coronary vasodilation but having no effect on microvascular endothelial function in patients with hypercholesterolemia. 138 An alternative successful strategy has been to lower steady-state concentrations of ⅐ NO-inactivating reactive oxygen species in animal models, via supplementation with antioxidant enzymes and oxidant scavengers. 139 -144 Several isoforms of PGHS and LOX are upregulated in both clinical and experimental cases of vascular disease, 21, 34, [145] [146] [147] [148] [149] [150] [151] with inhibition of these enzymes normalizing blood pressure in some cases. 150, [152] [153] [154] Our observations of catalytic ⅐ NO consumption by PGHS and LOX indicate novel mechanisms by which these enzymes might contribute to blood pressure regulation, in addition to the generation of vasoactive prostanoids. These are the first demonstrations of controlled ⅐ NO removal by regulated catalytic processes in mammalian cells. Recent studies using iNOS knockout mice demonstrated altered urinary prostaglandin E 2 levels, confirming direct interactions between ⅐ NO signaling and PGHS pathways in vivo. 99 Finally, the reactions of ⅐ NO and Currently, knowledge regarding interactions between lipid oxidation pathways and ⅐ NO is mainly from in vitro and animal model studies. Although great progress has been made at that level, a challenge for the future is to more incisively define which reactions are involved in the maintenance of vascular homeostasis and the initiation and progression of clinical vascular diseases. 
Acknowledgments
O'Donnell and Freeman Vascular Nitric Oxide and Eicosanoid Signaling
